36:T470,

Join Redalpine Senior Investment Manager Marc Mösser in conversation with three founders at the frontier of one of the most exciting intersections in modern science - techbio. Garry, CEO of Dalton; Rick, CEO of Helical; and Ula, CEO of LevelZeroHealth, take to the Protein Studios stage for an intimate 25-minute session that goes beyond the science to explore what it truly takes to build and scale a techbio company in the UK. Backed and supported by Redalpine, one of Europe's leading deep tech venture funds, these three founders offer a rare window into the founder-investor relationship at its most formative - the moments of conviction, the pivots, and the partnership that makes the difference between a promising idea and a category-defining company. For venture and angel investors, this is a front-row seat to three of the most promising companies emerging from the techbio space, and a masterclass in what a high-conviction VC bet looks like up close. For founders, it's an honest account of what building in the UK's techbio ecosystem really demands - and why the opportunity has never been greater.

37:T49b,

Marc has a background in life sciences and machine learning, with a masters in biochemistry from ETH Zürich and a phd in applied machine learning from the University of Oxford. During his time in oxford, Marc co-founded The Oxford Venture Capital Network, deepening the connection between the growing startup ecosystem at Oxford and the wider UK venture capital industry, later transitioning into VC by joining London-based pre-seed investor creator fund as one of the first investment partners. There, he led many of the fund's investments into deeptech, AI and life science startups across the UK and Europe.

Before joining redalpine, marc helped build chemify, a UK-based AI chemistry scale-up, from inception as the Chief of Staff and Director of Business Development. At Chemify, Marc worked closely with the CEO & Founder to raise >$40M in funding, scale the team to over 60 employees, and led the company's business development efforts, closing multiple commercial biotech partnerships.

Irene Jia

Session

Redalpine's Rising Stars in Biotech